TY - JOUR
T1 - Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
AU - Metcalf, Robert
AU - ferrarotto, renata
AU - Rodriguez, Cristina
AU - Muzaffar, Jameel
AU - Even, Caroline
AU - Perez, Cesar
AU - Van Hepen, Carla
AU - Olivia, Marc
AU - Xia, Bing
AU - Bowles, Daniel
AU - Popovtzer, Aharon
AU - Winquist, Eric
AU - Worth, Lori
AU - Hao, Desiree
AU - Kang, Hyunseok
AU - Hotte, Sebastien
AU - Stemmer, Salomon
AU - Mehra, Ranee
AU - Worden, Frances
AU - Ho, Alan
PY - 2022/6/2
Y1 - 2022/6/2
N2 - Background: Notch signaling plays a key role in ACC tumorigenesis. Notchmut are found in ̃20% of ACC tumors, which are aggressive with a poor prognosis. Approved or standard therapies for relapsed/metastatic ACC are lacking, regardless of Notch status. Investigational drug AL101, a γ-secretase inhibitor, blocks Notch signaling and inhibits tumor growth in Notchmut patient-derived ACC xenografts. AL101 has clinical activity at 4 mg once weekly (QW) with a disease control rate (DCR) of 68% (15% partial response, (PR)) and appears to be well tolerated. An additional cohort of 42 patients was enrolled at 6 mg QW, and here we update the final results of the trial. Methods: ACCURACY is an open-label, multicenter phase 2 study of AL101 (4 and 6 mg intravenous QW) in subjects with R/M ACC with Notch1-4mut (ASCO ‘19, Abstr TPS6098). Subjects required evidence of disease progression within 6 months of entry or newly diagnosed metastatic disease and an ECOG performance status of 0-1. The primary endpoint was overall response rate (ORR) by RECIST v1.1 (or modified MD Anderson bone criteria), as assessed by investigators. Secondary endpoints were ORR by central review, duration of response, and safety. The study provided ≥80% power to detect an increase of the ORR from 8% to 25% using a type I error of 5%. Results: A total of 82 subjects were enrolled in the study. The data cutoff date used was Oct 25, 2021. Most common (≥20%) treatment-related adverse events of all grades in the study were diarrhea (78%; grade 3 (gr3) 10%), fatigue (67%; gr3 6%), nausea (60%; gr3 7%). Pharmacokinetics (PK) and blood pharmacodynamics (PD) both displayed a dose dependent change in AL101 plasma concentration and modulation of Notch target gene expression (Hes1 and Hes4), respectively. Of the 77 evaluable subjects, there were 9 PRs (12%) and 44 SDs (57%) for a disease control rate of 69%. Conclusions: Investigational drug AL101 at both 4 and 6 mg QW appears to be well tolerable in Notchmut R/M ACC. Additional efficacy and PK/PD data will be presented Clinical trial information: NCT03691207.
AB - Background: Notch signaling plays a key role in ACC tumorigenesis. Notchmut are found in ̃20% of ACC tumors, which are aggressive with a poor prognosis. Approved or standard therapies for relapsed/metastatic ACC are lacking, regardless of Notch status. Investigational drug AL101, a γ-secretase inhibitor, blocks Notch signaling and inhibits tumor growth in Notchmut patient-derived ACC xenografts. AL101 has clinical activity at 4 mg once weekly (QW) with a disease control rate (DCR) of 68% (15% partial response, (PR)) and appears to be well tolerated. An additional cohort of 42 patients was enrolled at 6 mg QW, and here we update the final results of the trial. Methods: ACCURACY is an open-label, multicenter phase 2 study of AL101 (4 and 6 mg intravenous QW) in subjects with R/M ACC with Notch1-4mut (ASCO ‘19, Abstr TPS6098). Subjects required evidence of disease progression within 6 months of entry or newly diagnosed metastatic disease and an ECOG performance status of 0-1. The primary endpoint was overall response rate (ORR) by RECIST v1.1 (or modified MD Anderson bone criteria), as assessed by investigators. Secondary endpoints were ORR by central review, duration of response, and safety. The study provided ≥80% power to detect an increase of the ORR from 8% to 25% using a type I error of 5%. Results: A total of 82 subjects were enrolled in the study. The data cutoff date used was Oct 25, 2021. Most common (≥20%) treatment-related adverse events of all grades in the study were diarrhea (78%; grade 3 (gr3) 10%), fatigue (67%; gr3 6%), nausea (60%; gr3 7%). Pharmacokinetics (PK) and blood pharmacodynamics (PD) both displayed a dose dependent change in AL101 plasma concentration and modulation of Notch target gene expression (Hes1 and Hes4), respectively. Of the 77 evaluable subjects, there were 9 PRs (12%) and 44 SDs (57%) for a disease control rate of 69%. Conclusions: Investigational drug AL101 at both 4 and 6 mg QW appears to be well tolerable in Notchmut R/M ACC. Additional efficacy and PK/PD data will be presented Clinical trial information: NCT03691207.
M3 - Meeting Abstract
SN - 0732-183X
VL - 40
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 16
ER -
